{"name":"Rocket Pharmaceuticals","slug":"rocket-pharma","ticker":"RCKT","exchange":"NASDAQ","domain":"rocketpharma.com","description":"Rocket Pharmaceuticals is a clinical-stage gene therapy company focused on developing treatments for rare genetic disorders. The company's pipeline includes several programs targeting various indications, including Fanconi anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and more. With a strong focus on gene therapy, Rocket Pharmaceuticals aims to bring innovative treatments to patients with rare genetic diseases. As a leader in the gene therapy space, the company has established partnerships with leading research institutions and pharmaceutical companies to advance its pipeline.","hq":"Cranbury, NJ","founded":0,"employees":"","ceo":"Gaurav Shah","sector":"Gene Therapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$2.4B","metrics":{"revenue":150000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":142015000,"netIncome":-223123000,"cash":77558000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"RP-L301","genericName":"RP-L301","slug":"rp-l301","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"RP-L301","genericName":"RP-L301","slug":"rp-l301","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Rocket Pharmaceuticals reported its fourth quarter and full year 2023 financial results, highlighting a net loss of $43.6 million and $173.4 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-16","type":"deal","headline":"Rocket Pharmaceuticals Announces Collaboration with the National Institutes of Health (NIH) to Develop Gene Therapies for Rare Genetic Disorders","summary":"Rocket Pharmaceuticals announced a collaboration with the NIH to develop gene therapies for rare genetic disorders, expanding its pipeline and research capabilities.","drugName":"","sentiment":"positive"},{"date":"2023-08-14","type":"trial","headline":"Rocket Pharmaceuticals Announces Positive Interim Results from Phase 1/2 Clinical Trial of RP-L201 for Fanconi Anemia","summary":"Rocket Pharmaceuticals announced positive interim results from its Phase 1/2 clinical trial of RP-L201 for Fanconi anemia, demonstrating promising efficacy and safety.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNb19ydGY5aU9NSFNtYjhMaEVBbFI2Qndsa0V4V1NNQ3hub2hkNGdKRUFzRE1EcUJSdG8xdy1rLWVSQ3J0dk5JR1FlbWtfSjJnUDJQanBaRzR4dEhWbWVzWHhPRnU1SGU4V2hrVlVqQnM1X3JoQnlOWG1yVjRkRmRLVVRiQTBnTUFwaUtNdzZVNGo3S3VXR1hXbVd2a2NqSTkyUTNfNElLcUhXeE9xNHZJejJENkRoeV9fYlFXQkN3d2RhRE5qVDFCWQ?oc=5","date":"2026-03-29","type":"regulatory","source":"MedCity News","summary":"FDA Approval Makes Rocket Pharma Gene Therapy the First for Ultra-Rare Immune Disorder - MedCity News","headline":"FDA Approval Makes Rocket Pharma Gene Therapy the First for Ultra-Rare Immune Disorder","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOdUJoSFprR1dhSE0yM3FaMXdTaWN4Z0NiSmFVQ25CMnFoNXV2WFJzNXVlRUdVVmRESkpjcnlVTUZNTTBlc2J4eVNvN3NmS2pOZHl1VmtEQ09UMDVaNkZObGczbndubFRmYl9CSUtST2VYUGs2RGN6UW5yU2FsQW0zOERsZw?oc=5","date":"2026-03-27","type":"regulatory","source":"Seeking Alpha","summary":"Rocket Pharma wins FDA nod for gene therapy (RCKT:NASDAQ) - Seeking Alpha","headline":"Rocket Pharma wins FDA nod for gene therapy (RCKT:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxQb3pwVE5RSS1EdU5MNFZzVDN6d3JodDlIV09mYXo5V3NQeWl1em55dWtLY3c0VVhiX00yaGVBVi1IMFNqazhkbVRUclRNamV6LUo2X3J1LUF5dkR6YlBtZmo4cnhXWkhpYktZMEtCempJdV9XUnQ0Y29fZ1hSaVNpazNnY1JhMlBIaWNoSDBmaFRHNlU3YjhrSjVPa1dpVHMxSmxBRWhjbEJqZmltYUl6Y2R3TW9CWlo3alBDMDR6eEpVaUxhb0N3MDMzSnBheHBaSkRvOHpnWW52U1NRRFNWSE5tWmRQTUxYNEhwYURDTWdnS2JuWktyODhKZTdWa2FzdUtXRDBqcnNVX1FpVU5ORnluaERLZw?oc=5","date":"2026-03-27","type":"regulatory","source":"Business Wire","summary":"Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) - Business Wire","headline":"Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficie","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQb3czUmRyUjlrMTBtbUZOekVlN2E4ckUxTGEwWmVtekhCbmpybEQ1cV9yMXlOUVFrMXZuYTIzQVdXSXVrZUlfUG5xLWNOUjFFWlBGS011LTdwN1hLS0toYnBWbE0wNEVmT2V3eVhVVFZNd01ieTlHWGE2T2VaWXh4OXAtcF9uaF9hM28tUmdka3h4c040?oc=5","date":"2026-03-27","type":"pipeline","source":"Benzinga","summary":"Why Is Rocket Pharma Stock Soaring Friday? - Benzinga","headline":"Why Is Rocket Pharma Stock Soaring Friday?","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-25","type":"deal","source":"MSN","summary":"Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now? - MSN","headline":"Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now?","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5RTk1PaHRfMnk5b20tTXNPczZXWVh6YV8tMmNKSll5TmdRSXdqLVBnbzg4cVBmdTRXc095QW00VnJ5RjkyMVBiX3JtMk1QRnZtR3NvYUMwd1IzXzFkYkHSAWNBVV95cUxORW5fbzA2ZnU2cEwzVVFVeHA3RFkwNGZXX3YyQU5lQmhBQzJ4TV9Kd1kzQ0NTdEVlOU9HVHRxdlJvaWdfWEd3Ym9qM0VzR1EweklocmtBZy1CUEhEbFNUd1lXVms?oc=5","date":"2026-03-06","type":"regulatory","source":"Bitget","summary":"Rocket Pharma's PDUFA Date Looms as Legal Risks and Cash Burn Create a High-Stakes Approval Gamble - Bitget","headline":"Rocket Pharma's PDUFA Date Looms as Legal Risks and Cash Burn Create a High-Stakes Approval Gamble","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNYlFqeEp6dEhaOVAxWVl6a0xKY0lrR3dxWlVSa0FkVTQwYVg2Mm5wLUwxWW5RdXgtc0Jncl9zWkRHMjRZRWN6a2Y5bS0xaWhBbjNKTWZlZ0Y3SHdocnRJM00wVFRBR09IVGxLN1NNQ2lKTWhWaTRpZFpwTnhJR09TcVRXNzNfZ2JRY1AtSGktNzJRWTUwN2dIU2Vxa3ROOFJOd2Utb1ZJejktSlRHblNmdE9SMEtlVEQ2djJjanNR?oc=5","date":"2026-03-02","type":"pipeline","source":"Stock Titan","summary":"Rocket Pharmaceuticals (NASDAQ: RCKT) files $400M shelf to raise capital - Stock Titan","headline":"Rocket Pharmaceuticals (NASDAQ: RCKT) files $400M shelf to raise capital","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNZFVGVFBPR0JXRnN2ZXhCVG9nVDl4WWMtaGd6N1MxVnVFSHB0QVRjY0RlRnY4bFYzU1BmNU5WRFRpcTZkczhyUDdydi1CQXU0bGpEZXNKclZyS1l4eVVCOElTc2g2eTZBcWYxT2lTbXlhSHMwU1p2SVR2bzFDTWdza3habXMzM2hLTHVsdm9xVDgyV1dlR3hjYTZXWERUU25lcXhiNQ?oc=5","date":"2026-01-15","type":"regulatory","source":"RTTNews","summary":"Will The FDA's Decision On KRESLADI Propel Rocket Pharmaceuticals? - RTTNews","headline":"Will The FDA's Decision On KRESLADI Propel Rocket Pharmaceuticals?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQU1VtMGxBWXNKOG1jNUlmYzVhMmtRNzBSYnVDbnpwMlBDdEZGa2hvTEdhOXRSUG13bHpxUnMtUkdPVVlNak4zVmVIeThVd2lVd09sa3hlbElSQ0hLb0w0dk9TbDlVY0Y4VWZ2VUlUZFBVUWF2QXhkWS1zX3YxbDVINGphNEg2ZnJ1TVA0aVcwUTlRalFWUW0xcFRaa3lpSk1oQm9GSzh5c1NNbzkzT0NF?oc=5","date":"2025-12-26","type":"regulatory","source":"Seeking Alpha","summary":"Rocket Pharmaceuticals: Upside On LAD-I Approval And Amended Danon Program - Seeking Alpha","headline":"Rocket Pharmaceuticals: Upside On LAD-I Approval And Amended Danon Program","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQcDdRTzQzLWNrNGxkSXp3emVMLUtUZmljUHRBcTdsOUNuZVhTbVkxaHVRWjVHVXg4Ujc0SGc3anBGenBLLWxHd3JpUHhUZGViMzFDczB5OGFodEt1R0NRTlpab1ZLLTZXVE5SU1BRX0k2N2ZXZGd1UU1sbkUtV3VrOFdIZjBCUXJ4LWtyNkctRnEybUNib3RNQXZlUnpDNnJLSE9JSHlRQlNueTZkSHJoSjZZQVRJWDNnV0dYSU93RWtMZE5F?oc=5","date":"2025-09-01","type":"pipeline","source":"Investing.com","summary":"Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal moment - Investing.com","headline":"Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal moment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNbnlobWMzUlJ6Ym1PNERjejlKWkN5TlRSOE5jY3h6RlBrWXBJOERLTWJOU3hrX3g4RkVKdTZoSllnTWd2OFE5WGE3bzlhTGt6cVVNblVxMlJLb1Z6RnFnN1dGSm5aRERWdFFvLU5ibm10MXRxaEUyMnZFUzVFOXJXNzdUZzVrOUIyVmV1TU9YNmlleF9RdnVUcExISmZ5S3k1cE1aRHNxR2Q2dklvcUhaMlYyaURCVlpyZlBGVjJ1c1M4Y3I1ckVRekJWQlZEVTNUYnVOZk5fcU15dw?oc=5","date":"2025-08-20","type":"regulatory","source":"Reuters","summary":"Rocket Pharma's shares soar after US FDA lets gene therapy trial resume - Reuters","headline":"Rocket Pharma's shares soar after US FDA lets gene therapy trial resume","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Editas Medicine","CRISPR Therapeutics","Bluebird Bio"],"therapeuticFocus":["Rare Genetic Disorders","Gene Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":0,"period":"2022-12-31"},{"value":0,"period":"2021-12-31"},{"value":0,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":142015000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-223123000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":77558000,"cashHistory":[],"totalAssets":330449000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}